Vaxcyte, Inc. (PCVX) announced positive results from its Phase 1/2 trial for VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV) candidate. The vaccine demonstrated robust immune responses and a favorable safety profile, potentially positioning it as a competitive alternative to existing pneumococcal vaccines like Pfizer’s Prevnar 20.